- Home
- HRMY vs BAND Comparison
HRMY vs BAND Comparison
Compare HRMY & BAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | BAND |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HRMY | BAND |
|---|---|---|
| Price | $35.34 | $59.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $44.11 | $24.50 |
| AVG Volume (30 Days) | 910.7K | ★ 1.1M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $868,453,000.00 | $204,113,000.00 |
| Revenue This Year | $19.75 | $15.16 |
| Revenue Next Year | $12.88 | $6.18 |
| P/E Ratio | $65.09 | ★ N/A |
| Revenue Growth | 21.51 | ★ 25.26 |
| 52 Week Low | $25.52 | $12.50 |
| 52 Week High | $40.87 | $79.08 |
Technical Indicators
Market Signals| Indicator | HRMY | BAND |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 44.50 |
| Support Level | $35.05 | $14.01 |
| Resistance Level | $35.47 | $77.53 |
| Average True Range (ATR) | 1.59 | 6.11 |
| MACD | -0.20 | -1.68 |
| Stochastic Oscillator | 46.08 | 14.43 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About BAND Bandwidth Inc.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of its revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.